Sartorius Stedim Biotech presents new crossflow filtration system for process development
The ideal solution for scaling studies and low volume ultra- and diafiltration operations.
Sartorius Stedim Biotech (SSB) has launched SARTOFLOW Smart, the smart and easy benchtop crossflow system for optimized ultra- and diafiltration applications. It can ideally be used in many downstream processes, such as purification of vaccines, monoclonal antibodies and recombinant proteins. The system is suitable for flexible use in laboratory environments for process development and clinical trials as well as for cGMP environments.
The brand new system is equipped with a low shear 4-piston membrane pump that enables highest product yields to be achieved. In addition the pump provides a wide range of flow rates allowing to choose between membrane surface areas from 50 cm² to as much as 0.14 m².
The crossflow system is supplied with SSB’s intuitive and easy to use DCU-4 control unit, which, when combined with the company’s BioPAT SCADA, MFCS-4 software, provides data logging and export. Its touchscreen offers instant access to all critical process parameters and displays control and alarm functions. A logbook function stores alarms, set points and user logs.
The SARTOFLOW family of crossflow systems shares an unique operation design with a 7” touchscreen that supports the operator with interactive prompts for easy guidance through entire process sequences. Users can select predefined parameters to automatically run sequences for concentration, diafiltration, rinsing, filling, draining, flushing steps and tare functions.
An optional peristaltic diafiltration pump is available to load product or buffer as a discrete process step. Furthermore, several options are available to customize the system according to specific requirements. For example, a conductivity, pH or temperature probe can be installed in the recirculation vessel. The system can also be upgraded in the case of changing process requirements.
“SARTOFLOW Smart is a milestone development in the landscape of small crossflow systems. It combines outstanding technology with options that are normally only available with process systems. With an exceptionally wide working range of membrane surface areas, the system is the perfect tool for both R&D optimization trials and cGMP production,” stated Dr. Marc Jenke, expert for benchtop crossflow filtration systems at Sartorius Stedim Biotech.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...